EMEA-000069-PIP05-16

Key facts

Invented name
Nucala
Active substance
Mepolizumab
Therapeutic area
Pneumology-allergology
Decision number
P/0119/2017
PIP number
EMEA-000069-PIP05-16
Pharmaceutical form(s)
  • Solution for injection
  • Powder for solution for injection
Condition(s) / indication(s)
Treatment of nasal polyposis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
GSK Trading Services Limited
United Kingdom
Tel.: +44 2089904891
Fax: +44 2089903501
E-mail: eu.paediatric-plans.gsk.com
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating